Success Rates in Development Stage Dealmaking
Just how frequently do deals fail? To begin to answer the question, we looked back at 41 significant clinical-stage deals-those valued at over $20 million--signed by Big Pharma or Big Biotech in 2002 and 2003 to see what percentage of them is still ongoing.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.